Have a personal or library account? Click to login
Expression of p53 Protein Product in Triple Negative Breast Cancers and Relation with Clinical and Histopathological Parameters/ Експресија На Р53 Протеинскиот Продукт Кај Тројно Негативните Карциноми На Дојка Во Сооднос Со Клиничките И Хистопатолошките Параметри Cover

Expression of p53 Protein Product in Triple Negative Breast Cancers and Relation with Clinical and Histopathological Parameters/ Експресија На Р53 Протеинскиот Продукт Кај Тројно Негативните Карциноми На Дојка Во Сооднос Со Клиничките И Хистопатолошките Параметри

PRILOZI
Volume 36 (2015): Issue 1 (May 2015)
By: Dzengis Jasar,  Snezana Smichkoska,  Katerina Kubelka,  Vanja Filipovski and  Gordana Petrushevska  
Open Access
|Jun 2015

References

  1. 1. Tavassoli FA. Pathology of the Breast, 2nd ed. Stamford, Connecticut; Appleton & Lange; 1999.
    Search in Google Scholar
  2. 2. Moinfar F. ed. Essentials of Diagnostic Breast Pathology, Berlin: Heidelberg: Springer; 2007. 10.1007/978-3-540-45120-4
    Search in Google Scholar
  3. 3 Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008; 107: 309-330.10.1007/s10549-007-9556-1221762017377838
    Search in Google Scholar
  4. 4. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003; 21: 292-300.10.1002/humu.1017412619115
    Search in Google Scholar
  5. 5. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006; 13(2): 293-325.10.1677/erc.1.0117216728565
    Search in Google Scholar
  6. 6. Park D, Karesen R, Noren T, Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch. 2007; 451: 11-18.10.1007/s00428-007-0435-217554555
    Search in Google Scholar
  7. 7. De Azambuja E, Cardoso F, De Castro G, Colozzo M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart- Bebhart MJ, Paesmans M. Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12.155 patients. Br J Cancer. 2007; 96: 1504-1513.10.1038/sj.bjc.6603756235993617453008
    Search in Google Scholar
  8. 8. Eden P, Ritz C, Rose C, Ferno M, Peterson C."Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004; 40: 1837-1841.10.1016/j.ejca.2004.02.02515288284
    Search in Google Scholar
  9. 9. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003; 88: 1191-1198.10.1038/sj.bjc.6600886274757612698183
    Search in Google Scholar
  10. 10. Pease AC, Solas D, Sullivan EJ, Cronin MT, C. Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci USA. 1994; 91: 5022-5026.10.1073/pnas.91.11.5022439228197176
    Search in Google Scholar
  11. 11. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270: 467-470.10.1126/science.270.5235.4677569999
    Search in Google Scholar
  12. 12. Perou CM, Sorlie T, Eisen MB, van de Rijin M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikv A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D, Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
    Search in Google Scholar
  13. 13. Sorlie T, Perou CM, Tibshiranin R, Aas T, Geisler S, Johnsen H, Hasti T, Eisen MB, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen- Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869-10874.10.1073/pnas.1913670985856611553815
    Search in Google Scholar
  14. 14. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J,. Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA. 2006; 295(21): 2492-2502.10.1001/jama.295.21.249216757721
    Search in Google Scholar
  15. 15. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28(10): 1684-1691.10.1200/JCO.2009.24.928420194857
    Search in Google Scholar
  16. 16. Carey LA. Molecular intrinsic subtypes of breast cancer. In: UpToDate. Hayes DF, Dizon DS, eds. Waltham, MA: UpToDate; 2012. p. 77-84.
    Search in Google Scholar
  17. 17. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61-70.10.1038/nature11412346553223000897
    Search in Google Scholar
  18. 18. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat. 2011; 126(1): 185-192.10.1007/s10549-010-1113-7302607420711652
    Search in Google Scholar
  19. 19. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011; 29(29): 3885-3891.10.1200/JCO.2011.36.1105318909021900114
    Search in Google Scholar
  20. 20. Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea Ilies G, Bayakly AR, O'Regan RM, Vertino PM, Eley JW. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 2010; 116(11): 2549-2559.10.1002/cncr.2501620336785
    Search in Google Scholar
  21. 21. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006; 25(43): 5846-5853.10.1038/sj.onc.120987616998499
    Search in Google Scholar
  22. 22. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K,. Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109(1):123-139.10.1007/s10549-007-9632-6244310317578664
    Search in Google Scholar
  23. 23. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Banchard RA, Lee JC, King TC, Rosenberg CL. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009; 11(2): R18.10.1186/bcr2242268894619320967
    Search in Google Scholar
  24. 24. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: Implications for breast cancer screening recommendations. Cancer. 2011; 117(12): 2747-2753.10.1002/cncr.25862346124321656753
    Search in Google Scholar
  25. 25. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26(26): 4282-4288.10.1200/JCO.2008.16.6231636633518779615
    Search in Google Scholar
  26. 26. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretoy J, Theocharus C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009; 27(28): 4701-4708.10.1200/JCO.2008.21.707519720911
    Search in Google Scholar
  27. 27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37(9): 1217-1226.10.1016/j.humpath.2006.04.01516938528
    Search in Google Scholar
  28. 28. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011; 103(3): 250-263.10.1093/jnci/djq526310757021191117
    Search in Google Scholar
  29. 29. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012; 131(1): 159-167.10.1007/s10549-011-1702-0323794721830014
    Search in Google Scholar
  30. 30. Rosai J. Rosai and Ackerman’s Surgical Pathology, 9th ed. London; Mosby; 2004.
    Search in Google Scholar
  31. 31. American Joint Committee on Cancer - AJCC Cancer Staging Manual, 7th ed. New York: Springer-Verlag; 2010.
    Search in Google Scholar
  32. 32. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11 (3): 359-377.10.1038/bjc.1957.43207388513499785
    Search in Google Scholar
  33. 33. Genestie C, Zafrani B, Asselain B, Fourquet A, Rozan S, Validire P, Vincent-Salomon A, Sastre-Garau, X. Comparison of the prognostic value of Scarff- Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems. Anticancer Res. 1998;18(1B): 571-576.
    Search in Google Scholar
  34. 34. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.10.1111/j.1365-2559.1991.tb00229.x1757079
    Search in Google Scholar
  35. 35. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22(3): 207-219.10.1007/BF018408341391987
    Search in Google Scholar
  36. 36. Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F. Nottingham prognostic index in triple negative breast cancer: a reliable prognostic tool? BMC Cancer. 2011; 11: 299-308.
    Search in Google Scholar
  37. 37. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox BS, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt Sj, Scmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12: 207-219.10.1186/bcr2607294963720804570
    Search in Google Scholar
  38. 38. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple negative breast cancer. Cancer. 2007; 109: 25-32.10.1002/cncr.2238117146782
    Search in Google Scholar
  39. 39. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013; 66(6): 512-6.10.1136/jclinpath-2012-201085
    Search in Google Scholar
  40. 40. Pathmanathan N, Bilous AM. HER2 testing in breast cancer: an overview of current techniques and recent developments. Pathology. 2012; 44(7): 587-95.10.1097/PAT.0b013e328359cf9a
    Search in Google Scholar
  41. 41. Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34bE12) is an independent predictor of disease-free survival in patients with triple-negative tumors of the breast. J Clin Pathol. 2010; 63: 744-747.10.1136/jcp.2010.076653
    Search in Google Scholar
  42. 42. Gusterson B, Ross D, Heath V, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005; 7: 143-148. 43 Rakha EA, Reis-Filho JS, Ellis IO.Basal-like breast cancer: a critical review. J Clin Oncol. 2007; 26: 2568-2581.
    Search in Google Scholar
  43. 44. Cheang M, Voduc D, Bajdik C, Leung S, Mckinney S, Chia SK. Вasal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin Cancer Res. 2008;14: 1368-1376.10.1158/1078-0432.CCR-07-1658
    Search in Google Scholar
  44. 45. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 7.1 2007: 134.10.1186/1471-2407-7-134
    Search in Google Scholar
  45. 46. Salman MI, Elhefnawy NG, Shash LS. Morphological and immunohistochemical characteristics of triple negative and basal breast carcinoma. Egypt J Path. 2012; 32: 6-13.10.1097/01.XEJ.0000417553.95276.37
    Search in Google Scholar
  46. 47. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. 2000; 88: 804-813.10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y
    Search in Google Scholar
  47. 48. Carter CL, Allen C, Henderson DE. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer. 1989; 63: 181-187.10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
    Search in Google Scholar
  48. 49. Korkolis DP, Tsoli E, Fouskakis D, Yiotis G, Koullias J, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are inde pendent prognostic factors in breast cancer patients. Anticancer Res. 2004; 24: 2061-2068.
    Search in Google Scholar
  49. 50. Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep. 2005; 14: 337-343.
    Search in Google Scholar
  50. 51. Nakagawa M, Bando Y, Nagao T, Morimoto M, Takai C, Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Sasa M, Tangoku A. Expression of p53, Ki67, E-cadherin, N-cadherin and Topoisomerase 2A (TOP-2A) in triple negative breast cancer. Anticancer Res. 2011; 31: 2389-2393.
    Search in Google Scholar
  51. 52. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hammel N, Goffin JR, Wong N, Trudel M, Kapusta L Porter P, Akslen LA. Advances in brief the prognostic implication of the basal-like phenotype of BRCA1-related breast cancer (cyclin/high/p27low/p53/glomeruloid-microvascularproliferation). Cancer Res. 2004; 64: 830-835.10.1158/0008-5472.CAN-03-2970
    Search in Google Scholar
  52. 53. Lerma E, Peiro G, Ramon T, Fernandez S, Martinez D, Pons C, Munoz F, Sabate JM, Alonso C, Ojeda B, Prat J, Barnadas A. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basallike breast carcinomas). Mod Pathol. 2007; 20: 1200-1207.10.1038/modpathol.3800961
    Search in Google Scholar
  53. 54. Kreike B, van Kouwenhove M, Horlings H,Weigelt B, Peterse H, Bartelink H, van der Vijver M. Gene expression profiling and histopathological characterization of triple- negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9: R65.10.1186/bcr1771224266017910759
    Search in Google Scholar
  54. 55. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int Ј Clin Exp Pathol. 2009; 2: 444-455.
    Search in Google Scholar
  55. 56. Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ, Hoogerbrugge N, van Leeuwen I, Vasen HF, Cleton-Jansen AM, Kraan J, Houwing- Duistermaat JJ, Morreau H, Cornelisse CJ, Devilee P. Characterization of familial non-BRCA1/2 breast tumours by loss of heterozygosity and immunophenotyping. Clin Cancer Res. 2006; 12: 1693-1700. 10.1158/1078-0432.CCR-05-223016551851
    Search in Google Scholar
DOI: https://doi.org/10.1515/prilozi-2015-0031 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Journal RSS Feed
Language: English
Page range: 69 - 79
Published on: Jun 16, 2015
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
breast cancer,
triple negative,
p53 protein product
Related subjects:
Medicine,
Basic medical science,
History and ethics of medicine,
Clinical medicine,
Clinical medicine, other,
Social sciences,
Education,
Education, other

© 2015 Dzengis Jasar, Snezana Smichkoska, Katerina Kubelka, Vanja Filipovski, Gordana Petrushevska, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 36 (2015): Issue 1 (May 2015)Next article